FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 83199

SEC Filing■ Unclear/unknown

MU filed 4 on 2026-10-15

10 SOURCES CONFIRMED · FIRST SEEN 2026-10-15 00:00 UTC

KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES10
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A Form 4 discloses insider transactions; without buy/sell detail, market impact is indeterminate.

Insider filing alone carries limited directional signal
CATALYST TO WATCH

Details of transaction size and direction

MAIN RISK

Could signal insider selling if a sale

FULL DISPATCH

MU (CIK 0001224095) filed a 4 on 2026-10-15.

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

SUBJECTMicron · MU

04 RECEIPTS

THE SOURCE RECORD.

17 SOURCES CONFIRMED
№ 01secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 02secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 03secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 04secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 05secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 06secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 07secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 08secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 09secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 10secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 11secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 12secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 13secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 14secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 15secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 16secsec.gov · CONFIRMING2026-10-15 00:00 UTCOPEN RECEIPT →
№ 17secsec.gov · PRIMARY2026-10-15 00:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis — Almirall, S.A.2026-10-14 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome — Hoffmann-La Roche2026-10-14 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) — Ultragenyx Pharmaceutical Inc2026-10-14 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.